** Shares of Xilio Therapeutics XLO.O down 27% to 78 cents before the bell as co seeks equity raise
** Waltham, Massachusetts -based XLO commences public offering of pre-funded warrants and warrants to purchase shares without disclosing deal size
** Cancer immunotherapies firm plans to use net offering proceeds to advance development of product candidates, working capital among other purposes
** Leerink sole bookrunner for proposed offering
** Co has ~51.8 mln shares outstanding and ~37.2 mln shares of public float, per LSEG data
** Over the weekend, XLO presented updated Phase II data for evaluating vilastobart in combination with atezolizumab in patients with a type of colorectal cancer at the annual ASCO meeting in Chicago
** On Feb 12, XLO shares more than doubled to close at $1.48 after inking collaboration and option agreement with AbbVie ABBV.N
** XLO shares on Fri closed up 11% at $1.07
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.